PE20121430A1 - Compuestos de espiropiperidina como antagonistas de receptor orl-1 - Google Patents

Compuestos de espiropiperidina como antagonistas de receptor orl-1

Info

Publication number
PE20121430A1
PE20121430A1 PE2012000659A PE2012000659A PE20121430A1 PE 20121430 A1 PE20121430 A1 PE 20121430A1 PE 2012000659 A PE2012000659 A PE 2012000659A PE 2012000659 A PE2012000659 A PE 2012000659A PE 20121430 A1 PE20121430 A1 PE 20121430A1
Authority
PE
Peru
Prior art keywords
methyl
orl
pyrazol
pyran
difluoro
Prior art date
Application number
PE2012000659A
Other languages
English (en)
Spanish (es)
Inventor
Collado Ana Belen Benito
Blanco Celia Lafuente
Escribano Miguel Angel Toledo
Concepcion Pedregal-Tercero
Maria Angeles Martinez-Grau
Alma Maria Jimenez-Aguado
Buezo Nuria Diaz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20121430A1 publication Critical patent/PE20121430A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2012000659A 2009-11-16 2010-11-10 Compuestos de espiropiperidina como antagonistas de receptor orl-1 PE20121430A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
PE20121430A1 true PE20121430A1 (es) 2012-10-26

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000659A PE20121430A1 (es) 2009-11-16 2010-11-10 Compuestos de espiropiperidina como antagonistas de receptor orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (enExample)
EP (1) EP2501703B1 (enExample)
JP (1) JP5680101B2 (enExample)
KR (1) KR101363830B1 (enExample)
CN (1) CN102612520B (enExample)
AR (1) AR078863A1 (enExample)
AU (1) AU2010319581C1 (enExample)
CA (1) CA2796161C (enExample)
CO (1) CO6541545A2 (enExample)
CR (1) CR20130087A (enExample)
DK (1) DK2501703T3 (enExample)
DO (1) DOP2012000135A (enExample)
EA (1) EA020848B1 (enExample)
EC (1) ECSP12011902A (enExample)
ES (1) ES2435814T3 (enExample)
HN (1) HN2012001011A (enExample)
HR (1) HRP20130967T1 (enExample)
IL (1) IL219370A (enExample)
JO (1) JO2887B1 (enExample)
MA (1) MA33751B1 (enExample)
ME (1) ME01537B (enExample)
MX (1) MX2012005691A (enExample)
MY (1) MY160665A (enExample)
NZ (1) NZ600006A (enExample)
PE (1) PE20121430A1 (enExample)
PH (1) PH12012500969A1 (enExample)
PL (1) PL2501703T3 (enExample)
PT (1) PT2501703E (enExample)
RS (1) RS53018B (enExample)
SI (1) SI2501703T1 (enExample)
TW (1) TWI465453B (enExample)
UA (1) UA107943C2 (enExample)
WO (1) WO2011060035A1 (enExample)
ZA (1) ZA201202967B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201401661RA (en) 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
NZ739834A (en) 2012-10-02 2018-11-30 Bayer Cropscience Ag Heterocyclic compounds as pesticides
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
JP7146782B2 (ja) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
LT3589638T (lt) 2017-03-02 2021-06-10 Eli Lilly And Company Junginiai, naudingi ror-gama-t slopinimui
JP6766274B2 (ja) * 2017-03-02 2020-10-07 イーライ リリー アンド カンパニー Ror−ガンマ−tを阻害するのに有用な化合物
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
KR102746817B1 (ko) 2018-02-16 2024-12-24 스미토모 파마 아메리카, 인크. 염, 결정 형태 및 이들의 제조 방법
CA3121910A1 (en) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
AU2021257786A1 (en) 2020-04-14 2022-11-03 Sunovion Pharmaceuticals Inc. (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine for treating neurological and psychiatric disorders
IL318169A (en) 2020-08-26 2025-03-01 Vertex Pharma Apol1 inhibitors and methods of use are the same
AU2023218994A1 (en) * 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス.エイ. ノシセプチン受容体親和性を有するトリアゾスピロ化合物
NZ528978A (en) * 2001-04-18 2004-06-25 Euro Celtique S Spiropyrazole compounds
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
ATE396995T1 (de) * 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Orl−1受容体リガンドとしてのn置換スピロピペリジン化合物
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
KR20050043935A (ko) * 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Orl-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
CL2009000731A1 (es) * 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.

Also Published As

Publication number Publication date
WO2011060035A1 (en) 2011-05-19
JP5680101B2 (ja) 2015-03-04
CN102612520A (zh) 2012-07-25
KR101363830B1 (ko) 2014-02-14
TW201127841A (en) 2011-08-16
MA33751B1 (fr) 2012-11-01
PL2501703T3 (pl) 2014-02-28
IL219370A0 (en) 2012-06-28
AR078863A1 (es) 2011-12-07
CA2796161C (en) 2015-03-17
EA020848B1 (ru) 2015-02-27
PH12012500969A1 (en) 2013-01-07
EP2501703B1 (en) 2013-09-18
RS53018B (sr) 2014-04-30
IL219370A (en) 2015-01-29
DOP2012000135A (es) 2012-08-15
JP2013510859A (ja) 2013-03-28
EP2501703A1 (en) 2012-09-26
NZ600006A (en) 2014-05-30
AU2010319581C1 (en) 2014-05-15
AU2010319581B2 (en) 2013-12-19
MY160665A (en) 2017-03-15
CN102612520B (zh) 2015-04-08
DK2501703T3 (da) 2013-10-14
US8232289B2 (en) 2012-07-31
HN2012001011A (es) 2015-08-31
ECSP12011902A (es) 2012-07-31
US20110118251A1 (en) 2011-05-19
TWI465453B (zh) 2014-12-21
MX2012005691A (es) 2012-06-13
CR20130087A (es) 2013-04-17
ES2435814T3 (es) 2013-12-23
KR20130026523A (ko) 2013-03-13
AU2010319581A1 (en) 2012-06-07
HK1169988A1 (en) 2013-02-15
CA2796161A1 (en) 2011-05-19
UA107943C2 (xx) 2015-03-10
PT2501703E (pt) 2013-11-26
EA201290352A1 (ru) 2012-10-30
HRP20130967T1 (hr) 2013-11-22
ME01537B (me) 2014-04-20
ZA201202967B (en) 2013-09-25
CO6541545A2 (es) 2012-10-16
SI2501703T1 (sl) 2013-11-29
JO2887B1 (en) 2015-03-15

Similar Documents

Publication Publication Date Title
PE20121430A1 (es) Compuestos de espiropiperidina como antagonistas de receptor orl-1
DK2350090T3 (en) Spiro-oxindole compounds and their use as therapeutic agents
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20091884A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20081851A1 (es) Derivados de espiropiperidina-glicinamida
PE20110408A1 (es) Derivados de benzazepina y sus usos como antagonistas de histamina h3
PE20091353A1 (es) Nuevos compuestos heterociclicos
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PE20060586A1 (es) DERIVADOS DE PIRAZOLO [1,5-a]PIRIMIDINA COMO ANTAGONISTAS DEL RECEPTOR CRF
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20120110A1 (es) [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
PE20141578A1 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2
PE20091811A1 (es) DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1
PE20231215A1 (es) Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
PE20091678A1 (es) Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176
PE20091167A1 (es) Derivados heterociclicos con actividad sobre los receptores de ampa
PE20081900A1 (es) Heterociclos como antagonistas de orexina
PE20081574A1 (es) DERIVADOS DE INDOL-2-IL-CARBONIL-PIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR DE LA V1a
Takai et al. Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists

Legal Events

Date Code Title Description
FG Grant, registration